Skip to main content
BDTX
NASDAQ Life Sciences

Black Diamond 10-Q: $102M Cash Into H2 2028, Q3 Net Loss $10.0M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2
Mkt Cap
$106.864M
52W Low
$1.6
52W High
$4.94
52W Position info
25% above low
Off High info
60% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BDTX sits 25% above its 52-week low of $1.6.

Summary

Black Diamond's Q3 10-Q shows a $10.0 million quarterly net loss and $102.0 million in cash and investments, enough to fund operations into the second half of 2028 — before the Phase 3 trial that will require substantial new capital.


Key Events · Earnings and Guidance · BDTX

  • Q3 Net Loss of $10.0 Million

    The three-month net loss was $10.0 million ($0.17 per share) versus $8.5 million a year earlier; for the nine months, the net loss was $29.0 million against net income of $37.5 million in 2025, which included the $70.0 million Servier upfront.

  • $102.0M Cash Funds Operations Into H2 2028

    Cash, cash equivalents and investments totaled $102.0 million at September 30, 2026, down from $128.7 million at year-end 2025; management guides this funds planned operations into the second half of 2028.

  • Phase 3 Still Needs Substantial New Capital

    The filing states the company will need to raise substantial additional capital to initiate and complete the Phase 3 trial in frontline EGFR-NCM NSCLC, planned to start in Q2 2027 pending Cohort 4 safety data submission to FDA.

  • R&D Down, G&A Up Year Over Year

    Nine-month R&D fell to $21.4 million from $27.3 million as NSCLC trial costs declined $7.4 million, offset by $6.5 million of new GBM spending; G&A rose to $14.1 million from $12.6 million on higher IP-related and non-income tax expense.


Analysis · BDTX · Life Sciences

The clinical headline was already out this morning; what's new here is the money. Black Diamond ended September with $102.0 million in cash and investments, a balance it says funds operations into the second half of 2028 — a runway that comfortably covers the planned Q2 2027 Phase 3 start, though management states plainly it will need to raise substantial additional capital to run and complete that trial. The quarter itself was a $10.0 million net loss, and nine-month R&D fell to $21.4 million from $27.3 million as NSCLC spending wound down while the GBM program ramped up $6.5 million. G&A rose to $14.1 million from $12.6 million on IP and non-income tax costs. No going-concern language, no financing executed in the period — the ATM added nothing in Q3.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDTX was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDTX - Latest Insights

BDTX
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $2.01 info
Change: +$0.0100 (+0.50%) info
Market Cap: $106.864M info
BDTX
Nov 10, 2026, 6:28 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $2.01 info
Change: -$0.010 (-0.50%) info
Market Cap: $106.864M info
BDTX
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $2.01 info
Change: +$0.060 (+3%) info
Market Cap: $106.864M info
BDTX
May 21, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.19
Real-time Price: $2.01 info
Change: -$1.18 (-37%) info
Market Cap: $106.864M info
BDTX
May 21, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.27
Real-time Price: $2.01 info
Change: -$1.26 (-39%) info
Market Cap: $106.864M info